Skip to content

Study · Systematic review · 2015

7 results

Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials.

Gauthier S, Proaño JV, Jia J, Froelich L, Vester JC, Doppler E

Dementia and geriatric cognitive disorders26 Mar 2015Cited by 36 (Europe PMC)

PMID25832905 (opens in a new tab)DOI10.1159/000377672 (opens in a new tab)PepBankPUB-25832905
Source linkPubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In mild-to-moderate Alzheimer's disease, cerebrolysin improved cognitive function versus placebo at 4 weeks.

    In plain wordsIn mild-to-moderate Alzheimer's disease, cerebrolysin improved cognition more than placebo at 4 weeks.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseCognitive function at 4 weeks
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    30 ml/dayAs given in this study (human).

    Measurements

    Cognitive function standardized mean difference (SMD)
    −0.4 points
    Cerebrolysin versus placebo at 4 weeks
    95% confidence interval for Cognitive function standardized mean difference (SMD)
    −0.66 to −0.13 points
    Cerebrolysin versus placebo at 4 weeks
    P value for Cognitive function at 4 weeks
    0.0031
    Cerebrolysin versus placebo at 4 weeks

    Source sentences

    Summary
    Cerebrolysin was significantly more effective than placebo at 4 weeks regarding cognitive function (4 weeks: SMD -0.40 points; 95% CI -0.66 to -0.13; p = 0.0031;
    2 context sentences
    Summary · context
    This is a meta-analysis of randomized double-blind placebo-controlled clinical trials.
    Summary · context
    All randomized double-blind placebo-controlled studies on 30 ml/day of Cerebrolysin in mild-to-moderate AD were included.
  2. 02HumanSystematic reviewEfficacy outcome

    In mild-to-moderate Alzheimer's disease, cognitive function did not differ significantly between cerebrolysin and placebo at 6 months.

    In plain wordsIn mild-to-moderate Alzheimer's disease, cognition did not differ significantly between cerebrolysin and placebo at 6 months.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeCognitive function at 6 months
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    30 ml/dayAs given in this study (human).

    Measurements

    Cognitive function standardized mean difference (SMD)
    −0.37 points
    Cerebrolysin versus placebo at 6 months
    95% confidence interval for Cognitive function standardized mean difference (SMD)
    −0.9 to 0.16 points
    Cerebrolysin versus placebo at 6 months
    P value for Cognitive function at 6 months
    0.171
    Cerebrolysin versus placebo at 6 months

    Source sentences

    Summary
    6 months: SMD -0.37 points; 95% CI -0.90 to 0.16; p = 0.1710)
    2 context sentences
    Summary · context
    This is a meta-analysis of randomized double-blind placebo-controlled clinical trials.
    Summary · context
    All randomized double-blind placebo-controlled studies on 30 ml/day of Cerebrolysin in mild-to-moderate AD were included.
  3. 03HumanSystematic reviewEfficacy outcome

    In mild-to-moderate Alzheimer's disease, cerebrolysin improved global clinical change versus placebo at 4 weeks.

    In plain wordsIn mild-to-moderate Alzheimer's disease, cerebrolysin improved global clinical change more than placebo at 4 weeks.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseGlobal clinical change at 4 weeks
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Overall treatment effect · Nervous system and cognition
    Studied dose
    30 ml/dayAs given in this study (human).

    Measurements

    Global clinical change odds ratio (OR)
    3.32
    Cerebrolysin versus placebo at 4 weeks
    95% confidence interval for Global clinical change odds ratio (OR)
    1.2 to 9.21
    Cerebrolysin versus placebo at 4 weeks
    P value for Global clinical change at 4 weeks
    0.0212
    Cerebrolysin versus placebo at 4 weeks

    Source sentences

    Summary
    at 4 weeks and 6 months regarding global clinical change (4 weeks: OR 3.32; 95% CI 1.20-9.21; p = 0.0212;
    2 context sentences
    Summary · context
    This is a meta-analysis of randomized double-blind placebo-controlled clinical trials.
    Summary · context
    All randomized double-blind placebo-controlled studies on 30 ml/day of Cerebrolysin in mild-to-moderate AD were included.
  4. 04HumanSystematic reviewEfficacy outcome

    In mild-to-moderate Alzheimer's disease, cerebrolysin improved global clinical change versus placebo at 6 months.

    In plain wordsIn mild-to-moderate Alzheimer's disease, cerebrolysin improved global clinical change more than placebo at 6 months.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseGlobal clinical change at 6 months
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Overall treatment effect · Nervous system and cognition
    Studied dose
    30 ml/dayAs given in this study (human).

    Measurements

    Global clinical change odds ratio (OR)
    4.98
    Cerebrolysin versus placebo at 6 months
    95% confidence interval for Global clinical change odds ratio (OR)
    1.37 to 18.13
    Cerebrolysin versus placebo at 6 months
    P value for Global clinical change at 6 months
    0.015
    Cerebrolysin versus placebo at 6 months

    Source sentences

    Summary
    6 months: OR 4.98; 95% CI 1.37-18.13; p = 0.0150)
    2 context sentences
    Summary · context
    This is a meta-analysis of randomized double-blind placebo-controlled clinical trials.
    Summary · context
    All randomized double-blind placebo-controlled studies on 30 ml/day of Cerebrolysin in mild-to-moderate AD were included.
  5. 05HumanSystematic reviewEfficacy outcome

    In mild-to-moderate Alzheimer's disease, cerebrolysin improved combined global benefit versus placebo at 4 weeks.

    In plain wordsIn mild-to-moderate Alzheimer's disease, cerebrolysin improved combined global benefit more than placebo at 4 weeks.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseGlobal benefit at 4 weeks
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Overall treatment effect · Nervous system and cognition
    Studied dose
    30 ml/dayAs given in this study (human).

    Measurements

    Global benefit Mann-Whitney statistic (MW)
    0.57
    Cerebrolysin versus placebo at 4 weeks
    95% confidence interval for Global benefit Mann-Whitney statistic (MW)
    0.53 to 0.61
    Cerebrolysin versus placebo at 4 weeks
    P value for Global benefit at 4 weeks
    0.0006
    Cerebrolysin versus placebo at 4 weeks

    Source sentences

    Summary
    and at 4 weeks and 6 months regarding 'global benefit' (combined efficacy criteria; 4 weeks: MW 0.57, 95% CI 0.53-0.61; p = 0.0006;
    2 context sentences
    Summary · context
    This is a meta-analysis of randomized double-blind placebo-controlled clinical trials.
    Summary · context
    All randomized double-blind placebo-controlled studies on 30 ml/day of Cerebrolysin in mild-to-moderate AD were included.
  6. 06HumanSystematic reviewEfficacy outcome

    In mild-to-moderate Alzheimer's disease, cerebrolysin improved combined global benefit versus placebo at 6 months.

    In plain wordsIn mild-to-moderate Alzheimer's disease, cerebrolysin improved combined global benefit more than placebo at 6 months.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseGlobal benefit at 6 months
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Overall treatment effect · Nervous system and cognition
    Studied dose
    30 ml/dayAs given in this study (human).

    Measurements

    Global benefit Mann-Whitney statistic (MW)
    0.57
    Cerebrolysin versus placebo at 6 months
    95% confidence interval for Global benefit Mann-Whitney statistic (MW)
    0.53 to 0.61
    Cerebrolysin versus placebo at 6 months
    P value for Global benefit at 6 months
    0.001
    Cerebrolysin versus placebo at 6 months

    Source sentences

    Summary
    6 months: MW 0.57; 95% CI 0.53-0.61; p = 0.0010).
    2 context sentences
    Summary · context
    This is a meta-analysis of randomized double-blind placebo-controlled clinical trials.
    Summary · context
    All randomized double-blind placebo-controlled studies on 30 ml/day of Cerebrolysin in mild-to-moderate AD were included.
  7. 07HumanSystematic reviewSafety outcome

    In mild-to-moderate Alzheimer's disease trials, cerebrolysin safety was comparable to placebo.

    In plain wordsIn mild-to-moderate Alzheimer's disease trials, cerebrolysin safety was comparable to placebo.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeSafety
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    30 ml/dayAs given in this study (human).

    Source sentences

    Summary
    The safety aspects of Cerebrolysin were comparable to placebo.
    2 context sentences
    Summary · context
    This is a meta-analysis of randomized double-blind placebo-controlled clinical trials.
    Summary · context
    All randomized double-blind placebo-controlled studies on 30 ml/day of Cerebrolysin in mild-to-moderate AD were included.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.